# Prolia® (denosumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/denosumab

> The FDA approved Prolia® (denosumab), sponsored by AMGEN INC (AMGN), on September 28, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Prolia® (denosumab) FDA approved?

Yes. The FDA approved Prolia® (denosumab), sponsored by AMGEN INC (AMGN), on September 28, 2026. Press release filed with the SEC (EX-99): "On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab-adet) as a biosimilar to Xgeva® (denosumab)." [Calendar and source filings](https://sec-api.dev/pdufa/denosumab)

Source: Press release filed with the SEC (EX-99), accession 0001171843-26-007054, https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/pdufa/denosumab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Prolia® (denosumab) |
| Codes |  |
| Sponsor | AMGEN INC (AMGN) https://sec-api.dev/companies/amgn/catalysts |
| Indications | [osteoporosis in women](https://sec-api.dev/indications/osteoporosis-in-women) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### June 9, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125320 SUPPL-203 (Efficacy): submission_status AP, submission_status_date 20200609, review_priority STANDARD; sponsor_name AMGEN; product PROLIA (DENOSUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125320%22

### March 5, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125320 SUPPL-213 (Efficacy): submission_status AP, submission_status_date 20240305, review_priority STANDARD; sponsor_name AMGEN; product PROLIA (DENOSUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125320%22

### March 18, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: osteoporosis in women.
- First seen 2025-03-18, last confirmed 2026-06-16.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003438): "On 18 March 2025 , the Company announced the FDA acceptance of BLA for AVT 03 , a proposed biosimilar to Prolia and Xgeva (denosumab) ." https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-001514): "HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's") and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, developed by Alvotech, a proposed biosimilar of Prolia® (denosumab) and Xgeva® (denosumab)." https://www.sec.gov/Archives/edgar/data/1898416/000117184325001514/exh_991.htm
- SEC prospectus (424B) (accession 0000930413-26-001864): "In March 2025, the FDA accepted our partner's BLA for AVT03 as a proposed biosimilar to Prolia (denosumab) for the treatment of osteoporosis in women after menopause who are at high risk for bone fracture and Xgeva (denosumab) a prescription biologic medicine used to prevent fracture, spinal cord compression, or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001864/c116682_424b5.htm
- SEC prospectus (424B) (accession 0000930413-26-001857): "In March 2025, the FDA accepted our partner's BLA for AVT03 as a proposed biosimilar to Prolia (denosumab) for the treatment of osteoporosis in women after menopause who are at high risk for bone fracture and Xgeva (denosumab) a prescription biologic medicine used to prevent fracture, spinal cord compression, or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001857/c116682_424b5.htm

### May 22, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125320 SUPPL-219 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name AMGEN; product PROLIA (DENOSUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125320%22

### Sep 2025: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-11-10, last confirmed 2025-11-10.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-108821): "To a lesser extent, during the third quarter the Biosimilars portfolio also benefitted from contribution from new assets; Bildyos® (denosumab-nxxp) and Bilprevda® (denosumab-nxxp), which was approved by the FDA in September 2025, and Tofidence® (tocilizumab-bavi), which the company acquired in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1821825/000110465925108821/tm2530711d1_ex99-1.htm

### September 28, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-03, last confirmed 2026-11-03.
- Press release filed with the SEC (EX-99) (accession 0001171843-26-007054): "On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab-adet) as a biosimilar to Xgeva® (denosumab)." https://www.sec.gov/Archives/edgar/data/818686/000117184326007054/exh_991.htm
- SEC Form 10-Q (accession 0000818686-26-000006): "On September 28, 2026, we announced that the FDA approved DEGEVMATM (denosumab-adet) as a biosimilar to Xgeva® (denosumab)." https://www.sec.gov/Archives/edgar/data/818686/000081868626000006/teva-20260930.htm

## Same indication

- [Biosimilar](https://sec-api.dev/pdufa/biosimilar) (ALVO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/denosumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Prolia® (denosumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/denosumab

```bibtex
@misc{secapidev_pdufa_denosumab_20261116,
  title        = {Prolia® (denosumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/denosumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_denosumab_20261116","title":"Prolia® (denosumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/denosumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
